RxDoctor Payments DataLook up a doctor →

Benjamin Barenberg, MD

Urogynecology and Reconstructive Pelvic Surgery · Oklahoma City, OKNPI 1124255922

Payments from drug & device makers

$32,884in general payments, 2019–2025

Across 389 payments — averaging $84.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$21K
  • AMAG Pharmaceuticals, Inc.$5K
  • Ascend Therapeutics US, LLC$1K
  • Medtronic$1K
  • Astellas Pharma US Inc$716
  • Gynesonics, Inc.$419
  • plus $4K from 52 others

What the payments were for

  • Speaking & faculty fees$24,85076%
  • Travel & lodging$1120%
  • Food & beverage$7,56923%
  • Education$3421%
  • Gifts$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$83,488
Medicare patients
193
Services billed
1,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron68$40,125
GemtesaVibegron24$13,874
ProgesteroneProgesterone, Micronized115$8,390
Estradiol134$6,330
IntrarosaPrasterone (Dhea)14$3,657
Methenamine Hippurate55$3,535
Testosterone Cypionate45$2,381
Estradiol (Twice Weekly)Estradiol14$1,697
Oxybutynin Chloride ErOxybutynin Chloride81$1,517
Levothyroxine Sodium107$923
Spironolactone24$509
Np ThyroidThyroid,pork11$316
Tamsulosin Hcl20$316
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$178
Zolpidem Tartrate19$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$716$40,12568 claims
Sumitomo Pharma America, Inc.Gemtesa$95$13,87424 claims
AMAG Pharmaceuticals, Inc.Intrarosa$4,860$3,65714 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$65$923107 claims
Acella Pharmaceuticals, LLCNp Thyroid$15$31611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →